Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Reaffirmed by Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They presently have a $40.00 price objective on the specialty pharmaceutical company's stock. Needham & Company LLC's target price suggests a potential upside of 9.92% from the company's current price.

Several other equities analysts also recently issued reports on the stock. Piper Sandler reissued an "overweight" rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Friday, March 29th. Truist Financial upped their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a "buy" rating in a research report on Monday, February 26th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and issued a $37.00 target price (up previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $39.00.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded down $1.60 during midday trading on Thursday, reaching $36.39. 462,878 shares of the stock traded hands, compared to its average volume of 440,641. Collegium Pharmaceutical has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 30.84 and a beta of 1.03. The firm has a fifty day moving average price of $36.63 and a two-hundred day moving average price of $30.30. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The business had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. On average, equities research analysts forecast that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Scott Dreyer sold 23,560 shares of the firm's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $32.28, for a total transaction of $760,516.80. Following the completion of the transaction, the executive vice president now owns 111,322 shares of the company's stock, valued at approximately $3,593,474.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 3.69% of the company's stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently bought and sold shares of the business. SummerHaven Investment Management LLC raised its stake in shares of Collegium Pharmaceutical by 1.1% during the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company's stock valued at $1,048,000 after buying an additional 368 shares during the last quarter. Illinois Municipal Retirement Fund grew its holdings in Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company's stock valued at $612,000 after buying an additional 411 shares in the last quarter. West Tower Group LLC grew its stake in shares of Collegium Pharmaceutical by 101.8% in the 4th quarter. West Tower Group LLC now owns 892 shares of the specialty pharmaceutical company's stock valued at $27,000 after buying an additional 450 shares during the period. Maverick Capital Ltd. increased its stake in Collegium Pharmaceutical by 5.2% during the first quarter. Maverick Capital Ltd. now owns 11,296 shares of the specialty pharmaceutical company's stock worth $271,000 after acquiring an additional 555 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 0.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company's stock worth $1,718,000 after acquiring an additional 585 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.